COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland

BACKGROUND: In July 2021, a new variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the Delta lineage was detected in the United Kingdom (UK), named AY.4.2 or “Delta plus”. By October 2021, the AY.4.2 variant accounted for approximately 10-11% of cases in the UK. AY.4.2 was de...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerr, Steven, Vasileiou, Eleftheria, Robertson, Chris, Sheikh, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2022
Materias:
Research Theme 1: COVID-19 Pandemic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269984/
https://www.ncbi.nlm.nih.gov/pubmed/35802764
http://dx.doi.org/10.7189/jogh.12.05025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269984/
https://www.ncbi.nlm.nih.gov/pubmed/35802764
http://dx.doi.org/10.7189/jogh.12.05025

Ejemplares similares